GlassScriptPhysician profile
Cara R Roberson
NPI 1093057465
$5,616.87
in general payments reported to CMS, 2019-2025
27 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.49 · 2022: $667 · 2023: $1,540 · 2024: $1,708 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,857.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $951.82 | 2022-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $720.01 | 2022-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $696.56 | 2022-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.83 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $513.96 | 2022-2025 | Leqvio |
| Merck Sharp & Dohme LLC | $509.26 | 2022-2025 | Verquvo |
| Pfizer INC. | $455.83 | 2022-2025 | |
| Amgen INC. | $389.89 | 2022-2024 | Repatha |
| Novo Nordisk INC | $94.90 | 2021-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $85.28 | 2021-2023 | |
| Boston Scientific Corporation | $76.54 | 2023-2025 | Watchman Flx |
| Scpharmaceuticals INC. | $69.62 | 2023-2024 | |
| Bridgebio Pharma, INC. | $69.36 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $50.97 | 2022-2023 | Xarelto |
| Abbvie INC. | $37.73 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $29.12 | 2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $27.92 | 2023 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $26.15 | 2024 | Evkeeza |
| Abbott Laboratories | $24.16 | 2022 | |
| Angiodynamics, INC. | $19.79 | 2025 | Auryon Laser System 100-120 Vac |
| Heartflow, INC. | $19.05 | 2024 | |
| Philips North America LLC | $18.85 | 2023 | |
| Vital Connect, INC | $18.69 | 2024 | Vitalpatch Rtm |
| Baxter Healthcare | $18.00 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $17.01 | 2025 | |
| Daxor Corporation | $13.80 | 2023 | Bva-100 |
| Vivaquant INC, Dba Rhythm Express | $11.77 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.